C
Cinzia Orlandini
Researcher at University of Pisa
Publications - 52
Citations - 3551
Cinzia Orlandini is an academic researcher from University of Pisa. The author has contributed to research in topics: Epirubicin & Gemcitabine. The author has an hindex of 27, co-authored 52 publications receiving 3314 citations. Previous affiliations of Cinzia Orlandini include University of Genoa.
Papers
More filters
Journal ArticleDOI
Phase III Trial of Infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) Compared With Infusional Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) As First-Line Treatment for Metastatic Colorectal Cancer: The Gruppo Oncologico Nord Ovest
Alfredo Falcone,Sergio Ricci,Isa Brunetti,Elisabetta Pfanner,Giacomo Allegrini,C. Barbara,Lucio Crinò,Giovanni Benedetti,W. Evangelista,Laura Fanchini,Enrico Cortesi,V. Picone,Stefano Vitello,Silvana Chiara,Cristina Granetto,Gianfranco Porcile,Luisa Fioretto,Cinzia Orlandini,Michele Andreuccetti,Gianluca Masi +19 more
TL;DR: The FOLFOXIRI regimen improves RR, PFS, and OS compared with FOLFIRI, with an increased, but manageable, toxicity in patients with metastatic colorectal cancer with favorable prognostic characteristics.
Journal ArticleDOI
Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine.
Elisa Giovannetti,Mario Del Tacca,Valentina Mey,Niccola Funel,Sara Nannizzi,Sergio Ricci,Cinzia Orlandini,Ugo Boggi,Daniela Campani,Marco Del Chiaro,Mauro Iannopollo,Generoso Bevilacqua,Franco Mosca,Romano Danesi +13 more
TL;DR: It is suggested that the expression levels of hENT1 may allow the stratification of patients based on their likelihood of survival, thus offering a potential new tool for treatment optimization.
Journal ArticleDOI
Survival of metastatic breast carcinoma patients over a 20-year period: a retrospective analysis based on individual patient data from six consecutive studies.
TL;DR: The expectation of improvement in patient survival with administration of new chemotherapy agents for metastatic breast carcinoma is not consistently supported by data from clinical trials, which are often underpowered and have not detected moderate survival advantage.
Journal ArticleDOI
The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients
Marzia Del Re,Elisa Biasco,Stefania Crucitta,Lisa Derosa,Eleonora Rofi,Cinzia Orlandini,Mario Miccoli,Luca Galli,Alfredo Falcone,G. Jenster,Ron H.N. van Schaik,Romano Danesi +11 more
TL;DR: This study demonstrates that plasma-derived exosomal RNA is a reliable source of AR-V7 that can be detected sensitively by ddPCR assay and shows that resistance to hormonal therapy may be predicted by AR-v7, making it a clinically relevant biomarker.
Journal ArticleDOI
Correlation of CDA, ERCC1, and XPD Polymorphisms with Response and Survival in Gemcitabine/Cisplatin–Treated Advanced Non–Small Cell Lung Cancer Patients
Carmelo Tibaldi,Elisa Giovannetti,Enrico Vasile,Valentina Mey,A.C. Laan,S. Nannizzi,R. Di Marsico,Andrea Antonuzzo,Cinzia Orlandini,S. Ricciardi,M. Del Tacca,G.J. Peters,Alfredo Falcone,Romano Danesi +13 more
TL;DR: The role of CDA Lys27Lys polymorphism is suggested as a possible predictive marker of activity, toxicity, TTP, and OS in advanced NSCLC patients treated with cisplatin and gemcitabine.